The role of Neuropilin-1 in COVID-19.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
01 2021
Historique:
entrez: 4 1 2021
pubmed: 5 1 2021
medline: 13 1 2021
Statut: epublish

Résumé

Neuropilin-1 (NRP-1), a member of a family of signaling proteins, was shown to serve as an entry factor and potentiate SARS Coronavirus 2 (SARS-CoV-2) infectivity in vitro. This cell surface receptor with its disseminated expression is important in angiogenesis, tumor progression, viral entry, axonal guidance, and immune function. NRP-1 is implicated in several aspects of a SARS-CoV-2 infection including possible spread through the olfactory bulb and into the central nervous system and increased NRP-1 RNA expression in lungs of severe Coronavirus Disease 2019 (COVID-19). Up-regulation of NRP-1 protein in diabetic kidney cells hint at its importance in a population at risk of severe COVID-19. Involvement of NRP-1 in immune function is compelling, given the role of an exaggerated immune response in disease severity and deaths due to COVID-19. NRP-1 has been suggested to be an immune checkpoint of T cell memory. It is unknown whether involvement and up-regulation of NRP-1 in COVID-19 may translate into disease outcome and long-term consequences, including possible immune dysfunction. It is prudent to further research NRP-1 and its possibility of serving as a therapeutic target in SARS-CoV-2 infections. We anticipate that widespread expression, abundance in the respiratory and olfactory epithelium, and the functionalities of NRP-1 factor into the multiple systemic effects of COVID-19 and challenges we face in management of disease and potential long-term sequelae.

Identifiants

pubmed: 33395426
doi: 10.1371/journal.ppat.1009153
pii: PPATHOGENS-D-20-01906
pmc: PMC7781380
doi:

Substances chimiques

Neuropilin-1 144713-63-3

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1009153

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Science. 2020 Nov 13;370(6518):856-860
pubmed: 33082293
Cell Death Dis. 2019 Jan 25;10(2):67
pubmed: 30683854
J Biol Chem. 2015 Dec 4;290(49):29120-6
pubmed: 26451046
Science. 2020 Nov 13;370(6518):861-865
pubmed: 33082294
Asian Pac J Allergy Immunol. 2020 Jun;38(2):69-77
pubmed: 32563234
Neurocrit Care. 2020 Jul 13;:
pubmed: 32661794
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):629-630
pubmed: 32405602
Arthritis Rheum. 2010 Jan;62(1):179-90
pubmed: 20039409
Oncogene. 2010 Apr 22;29(16):2381-92
pubmed: 20140015
Adv Exp Med Biol. 2002;515:55-69
pubmed: 12613543
Sci Adv. 2020 Jul 31;6(31):
pubmed: 32937591
Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16157-62
pubmed: 19805273
J Neuroimmune Pharmacol. 2020 Sep;15(3):359-386
pubmed: 32696264
Pharm Res. 2010 Mar;27(3):468-79
pubmed: 20087632
Dis Markers. 2015;2015:506428
pubmed: 25873749
Blood. 2009 May 21;113(21):5176-85
pubmed: 19270265
EMBO J. 2020 Oct 15;39(20):e106230
pubmed: 32876341
ACS Chem Neurosci. 2020 May 6;11(9):1200-1203
pubmed: 32283006
Front Immunol. 2017 Oct 10;8:1228
pubmed: 29067024
Cell Tissue Res. 2001 Aug;305(2):275-84
pubmed: 11545265
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Nat Commun. 2015 Feb 11;6:6240
pubmed: 25670642
Science. 2017 May 26;356(6340):
pubmed: 28495876
Am J Respir Crit Care Med. 2020 Nov 20;:
pubmed: 33217246
Am J Otolaryngol. 2020 Sep - Oct;41(5):102581
pubmed: 32563019
J Korean Med Sci. 2013 Oct;28(10):1435-42
pubmed: 24133346
Development. 2011 Sep;138(17):3723-33
pubmed: 21828096
Semin Cell Dev Biol. 2013 Mar;24(3):172-8
pubmed: 23319134
J Biol Chem. 2007 Aug 17;282(33):24049-56
pubmed: 17575273
Sci Rep. 2019 Sep 16;9(1):13342
pubmed: 31527750
Glia. 2016 Jun;64(6):923-36
pubmed: 26880314
mSphere. 2019 May 22;4(3):
pubmed: 31118303
PLoS Genet. 2017 Oct 23;13(10):e1007048
pubmed: 29059194
Cardiovasc Res. 2015 Nov 1;108(2):288-98
pubmed: 26410366
Curr Opin Hematol. 2016 May;23(3):260-7
pubmed: 26849476
Adv Exp Med Biol. 2020;1223:31-67
pubmed: 32030684
Chem Senses. 2017 Sep 1;42(7):513-523
pubmed: 28531300
Rhinology. 2020 Jun 1;58(3):302-303
pubmed: 32319971
FEBS J. 2018 Apr;285(7):1290-1304
pubmed: 29430837
PLoS Genet. 2012 Aug;8(8):e1002896
pubmed: 22927827
Int J Mol Sci. 2019 Jan 23;20(3):
pubmed: 30678134
Sci Immunol. 2018 Mar 16;3(21):
pubmed: 29549139

Auteurs

Bindu S Mayi (BS)

Department of Basic Sciences, Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Clearwater, Florida, United States of America.

Jillian A Leibowitz (JA)

Dr. Kiran C. Patel College of Osteopathic Medicine, Fort Lauderdale, Florida, United States of America.

Arden T Woods (AT)

Dr. Kiran C. Patel College of Osteopathic Medicine, Fort Lauderdale, Florida, United States of America.

Katherine A Ammon (KA)

USF Morsani College of Medicine, Tampa, Florida, United States of America.

Alphonse E Liu (AE)

Dr. Kiran C. Patel College of Osteopathic Medicine, Fort Lauderdale, Florida, United States of America.

Aarti Raja (A)

Department of Biological Sciences, Halmos College of Arts and Sciences, Nova Southeastern University, Fort Lauderdale, Florida, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH